
The UK National Screening Committee reviewed the introduction of an artificial intelligence screening tool in the diabetic eye screening programme.
The review, published in The Lancet, found that there is positive evidence in test performance to support the use of automated retinal imaging analysis software (ARIAS) in the UK National diabetic screening pathway – a tool Scotland has used for over a decade. However, issues with impacts on downstream clinical results and any wider social impacts or ethical consideration were still being explored.
Following previous research from 2019 and 2021, the committee highlighted that the screening programme is resource intensive, and its costs are expected to rise with projected increases in diabetes prevalence. Therefore, the cost-effective suggestion proposed was to screen patients using ARIAS before human grading, or to replace the primary human grader.
Register now to continue reading
Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.
Register
Already have an account? Sign in here